| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-10-0073 |
| P698 | PubMed publication ID | 20571072 |
| P50 | author | Georgia Beasley | Q42842714 |
| P2093 | author name string | M Angelica Selim | |
| Sin-Ho Jung | |||
| Douglas S Tyler | |||
| Francis Ali-Osman | |||
| Yasunori Yoshimoto | |||
| Scott K Pruitt | |||
| Hiroaki Toshimitsu | |||
| Jin S Yoo | |||
| James Padussis | |||
| Christina K Augustine | |||
| Nicole McMahon | |||
| Patricia A Zipfel | |||
| James Burchette | |||
| P2860 | cites work | Cancer statistics, 2009 | Q29547625 |
| The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells | Q40322004 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 2090-2101 | |
| P577 | publication date | 2010-06-22 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy | |
| P478 | volume | 9 |
| Q35471445 | A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. |
| Q36744566 | Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma |
| Q36072803 | Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model |
| Q39540154 | Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. |
| Q47684992 | Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors |
| Q28237892 | Copper is required for oncogenic BRAF signalling and tumorigenesis |
| Q37061029 | Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems |
| Q36563659 | Genetics of melanoma |
| Q39168954 | Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies |
| Q35506764 | In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma |
| Q35928707 | Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth |
| Q38187595 | Isolated limb infusion as a model to test new agents to treat metastatic melanoma |
| Q38867762 | Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy |
| Q37943015 | Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion |
| Q59022306 | Molecular Dynamics Simulation of VEGFR2 with Sorafenib and Other Urea-Substituted Aryloxy Compounds |
| Q39107981 | Potential therapeutic targets of epithelial-mesenchymal transition in melanoma |
| Q27001734 | Progression of cutaneous melanoma: implications for treatment |
| Q37812815 | Regional treatment strategies for in-transit melanoma metastasis |
| Q34497045 | Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma |
| Q35676344 | Resveratrol and clofarabine induces a preferential apoptosis-activating effect on malignant mesothelioma cells by Mcl-1 down-regulation and caspase-3 activation |
| Q37509699 | SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma |
| Q26747666 | Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma |
| Q34222257 | Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma |
| Q39013913 | Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma |
| Q37308167 | The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells |
| Q38532696 | The current management of brain metastasis in melanoma: a focus on riluzole |
| Q37951743 | Towards new therapeutic approaches for malignant melanoma |
| Q27323005 | Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo |
Search more.